The Accurun 501 C. difficile control from SeraCare Life Sciences, Milford, Mass, is the company’s first molecular control product targeting hospital-acquired infections. Formulated for use with in vitro diagnostics that detect C. difficile DNA in human stool samples, the control is manufactured from cultured Clostridium bacteria of four different strains or species that arrive in a set of four vials. At delivery, the bacteria are inactivated and in a human synthetic stool matrix. The control is ready to use in assays that detect C. difficile DNA with any transport system. The Accurun 501 is intended not only to estimate laboratory testing performance, but to also identify analytical errors and monitor the entire testing process for improved quality control. For more information, visit SeraCare Life Sciences.
July 23, 2019
January 27, 2005